Daix (France), Long Island City (New York, United States), May 23, 2022 – Inventiva (EuronextParisandNasdaq:IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the Company’s leadership will participate in two upcoming investors conferences in May and June 2022.
Read more at globenewswire.comInventiva announces participation at several investors conferences in May and June 2022
Globe Newswire - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
/Salesforce%20Inc%20logo%20on%20building-by%20Sundry%20Photography%20via%20Shutterstock.jpg)